China
Africa
Explore chapters and articles related to this topic
Decidualization Resistance
Published in Carlos Simón, Carmen Rubio, Handbook of Genetic Diagnostic Technologies in Reproductive Medicine, 2022
Irene Muñoz-Blat, Nerea Castillo-Marco, Teresa Cordero, Carlos Simón, Tamara Garrido-Gómez
Our transcriptomic results revealed altered gene expression during in vitro decidualization of hESCs from former patients with sPE. Among the 129 genes with altered expression, the gene encoding Annexin A2 (ANXA2) was further analyzed (26). This gene is associated with the first steps of embryo adhesion during the implantation process (48). ANXA2 is widely expressed in the placenta and its defective activity could cause fibrinolytic deficiency linked with increasing thrombosis and PE predisposition (49). We studied the role of ANXA2 in defective decidualization to evaluate its potential for being a maternal biomarker for sPE prediction (50). Deficient decidualization was detected in an in vitro model using small interfering RNA (siRNA) for ANXA2 in hESCs from control individuals. In addition, blocking ANXA2 expression during pregnancy in an in vivo knockout mouse model resulted in deficient implantation and placentation. Thus, these results support the occurrence of decidualization resistance in women with sPE at the time of delivery and propose ANXA2 as a possible biomarker to determine the risk of PE (50). Together, these results support the maternal contribution to PE.
Orlistat as a FASN inhibitor and multitargeted agent for cancer therapy
Published in Expert Opinion on Investigational Drugs, 2018
Alejandro Schcolnik-Cabrera, Alma Chávez-Blanco, Guadalupe Domínguez-Gómez, Lucia Taja-Chayeb, Rocio Morales-Barcenas, Catalina Trejo-Becerril, Enrique Perez-Cardenas, Aurora Gonzalez-Fierro, Alfonso Dueñas-González
Annexin A2 (also called p36, calpactin I, lipocortin II, chromo bindin VIII, or placental anticoagulant protein IV) is a 36 kDa protein. It has been reported that annexin A2 (ANXA2) plays a role in exocytosis, endocytosis, and membrane trafficking. Its depletion correlates with apoptotic death induced by p53-mediated pathways [91]. Annexin A is over-expressed in at least a dozen of malignancies [92]. Based on its role in cancer development and progression, its targeting has been evaluated in preclinical models. In fact, the anti-ANXA2 monoclonal antibody has shown in a preclinical model of breast carcinoma, a potent and durable antitumor effect lasting up to 172 days, with a 76% tumor growth inhibition with no adverse effects [93]. These data encourage the development of agents targeting ANXA2 for cancer treatment.
Annexin A2 promotes development of retinal neovascularization through PI3K/ AKT signaling pathway
Published in Current Eye Research, 2022
Chenyue Li, Zichang Zhao, Shihong Zhao
Annexin A2 (ANXA2), a 39 kDa member of the annexin family of Ca2+-dependent, phospholipid-binding proteins, is expressed in the majority of cells and tissues.6,7 ANXA2 is a pleiotropic protein and involved in multicellular biological functions such as cell proliferation, differentiation, cell motility and also plays an important role in cytoskeletal organization, exocytosis, endocytosis, invasion, metastasis, fibrinolysis, and ion channel formation.7
Human oncogenic viruses: an overview of protein biomarkers in viral cancers and their potential use in clinics
Published in Expert Review of Anticancer Therapy, 2022
By applying both bioinformatics and experimental analysis, the researchers evaluated the biomarker potential of ANXA2 in cervical cancer. First, through bioinformatics analysis, the researchers showed that ANXA2 is up-regulated and associated with cervical cancer prognosis. Second, to confirm the final results, the researchers performed immunohistochemical staining on cervical cancer and normal tissues and re- demonstrated up-regulation of ANXA2 [87].